Valerie Yang: Such a pleasure to chair the Sarcoma Track at the Singapore Society of Oncology (SSO) Annual Scientific Meeting 2024

Valerie Yang, Consultant at National Cancer Centre Singapore, shared a post on LinkedIn:

“Such a pleasure to chair the Sarcoma Track at the Singapore Society of Oncology (SSO) Annual Scientific Meeting 2024 where we discussed some key clinical trials presented at American Society of Clinical Oncology (ASCO) Annual Meeting this year.

As always, we delved into what these findings really mean, how this should change our practice, and what it actually means for our patients.

Shaun Ho – SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma

Lim Jianri – Final results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306

Matilda Lee – Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial

Jianbang Chiang – Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma

Grateful to all our speakers, chairs and audience!”

Source: Valerie Yang/LinkedIn